BID Equity merges Carenity to build European clinical data group.

BID Equity has acquired Paris-based patient community Carenity and will merge it with two existing portfolio companies to assemble a broader clinical data and services business. The combination brings together digital patient engagement, eClinical systems and medical-device software to address demand for integrated real‑world evidence (RWE) and trial optimization tools across Europe.

The private equity firm is consolidating XClinical, Fortress Medical Systems and Carenity into a single data‑science platform designed to span the full clinical development lifecycle. The refreshed group aims to offer sponsors and contract research organisations a one‑stop capability for patient recruitment, electronic data capture and post‑market evidence generation.

Carenity, founded in 2011 and headquartered in Paris, operates a social platform that connects patients and caregivers across around 1,000 chronic and rare conditions. The site reports an active community of approximately 500,000 registered users and monetises anonymised patient insights for RWE projects, trial feasibility and scientific communication.

Advising sell‑side in the transaction, Corum Group managed an auction process that drew interest from both strategics and financial sponsors despite pandemic volatility. Corum's deal team highlighted strong appetite for assets that provide direct patient access and compliant real‑world data — capabilities that buyers see as strategic for shortening recruitment cycles and enriching evidence packages.

Industry context: demand for RWE and patient‑centric platforms has surged as pharma and medical device makers increasingly incorporate real‑world datasets into regulatory submissions and commercial strategies. Investors have responded with roll‑ups and bolt‑on buys across Europe, a pattern mirrored by this three‑way consolidation. Analysts expect double‑digit growth in the market for patient data services and trial‑enabling technologies over the coming five years, driven by decentralised trial models and regulatory openness to RWE.

For BID Equity, the play is a classic operational consolidation: combining community reach, clinical software and device connectivity to create cross‑sell opportunities and reduce client procurement complexity. Potential synergies include faster site selection and recruitment from Carenity's community, integrated eClinical workflows from XClinical, and safety/technical integrations via Fortress Medical.

Looking ahead, the new group will target pharma sponsors, CROs and health systems that require end‑to‑end digital support for trials and evidence generation. The move also signals continued private equity momentum in European healthtech, where owners favour platform builds to capture recurring revenues and scale clinical offerings across markets.

Details on financial terms were not disclosed. Corum will discuss the transaction and broader software M&A trends during its upcoming webcast on private equity in technology markets.